Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
09/2010
09/14/2010US7795407 Metastatic breast and colon cancer regulated genes
09/14/2010US7795386 selectively inhibit alpha v beta 3 integrin; used in the treatment of diseases associated with angiogenesis and cancer
09/14/2010US7795302 use of topical formulation for treating rosacea containing a combination of an antimicrobial and at least one of non-retinoid inhibitor of one of nuclear factor-k-beta, AP-1 protein, matrix metalloproteinases, CD14
09/14/2010US7795301 preventing myxoviruses infection using 3-(acetylamino)-2-{3-(acetylamino)-4-{[amino(imino)methyl]amino}-6-carboxy-3,4-dihydro-2H-pyran-2-yl)-1-[1,2-dihydroxyethyl]-19,20-dihydroxy-3,16-dioxo-2,17-dioxa-4,15-diazaicos-1-yl}-4-{[amino(imino)methyl]-amino}-3,4-dihydro-2H--pyran-6-carboxylic acid; viricides
09/14/2010US7795293 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
09/14/2010US7795235 Semi-soft c-class immunostimulatory oligonucleotides
09/14/2010US7795229 beta-lactam compounds having a C-glycoside in the molecule, in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor selected from atorvastatin and rosuvastatin; synergistic
09/14/2010US7795212 such as viral myocarditis (Coxsackie virus, echovirus, polio virus) or dilated (congestive) cardiomyopathy, by binding ErbB2-ErbB4 receptors; atpase inhibitors
09/14/2010US7795204 supplementing the diet of an athlete with substances which increase the concentration of nitric oxide (NO) or increase its half life in the body, in combination with a source of amino acids, may provide surprising enhancement of an athlete's muscle
09/14/2010US7794995 use of several sequential steps, including subcellular fractionation to isolate a plasma membrane fraction and the use of gel filtration or chromatography that separates molecules according to their size or affinity; drug screening
09/14/2010US7794929 Detecting a colorectal cancer and/or gastric cancer, detecting selective hybridization of nucleic acid, therapeutic treatment of a cancer, a kit contains oligonucleotide
09/14/2010US7794927 Method for identifying agonists or antagonists of the G-protein coupled receptor mas-like 1
09/14/2010US7794752 Preparation and administration form comprising an acid-labile active compound
09/14/2010US7794744 Nutritional modules
09/14/2010US7794739 composition for applying to skin containing at least one purine nucleic acid-related substance chosen from adenosine monophosphate and salt thereof, at least one pyrimidine nucleic acid-related substance chosen from uridine monophosphate and salt thereof, and at least one additive; anti-aging, anti-acne
09/14/2010US7794731 Use of flagellin in the immunotherapy of Yersinia pestis
09/14/2010US7794722 Natural killer T-cell agonists; vaccines; antigen presenting cells
09/14/2010US7794715 T-cell immune response cDNA 7 (TIRC7) antagonist; rheumatoid arthritis; comprising all three complementarity determining regions (CDRs) of the VH and all three complementarity determining regions (CDRs) of the VL variable regions
09/14/2010CA2521325C Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
09/14/2010CA2447834C A prepreg, a composite and their uses
09/14/2010CA2443623C A jasmonate pharmaceutical composition for treatment of cancer
09/14/2010CA2432009C Pharmaceutical preparations comprising a salt of an antibiotic and an antiphlogistic and use thereof
09/14/2010CA2386231C Membrane translocating peptide drug delivery system
09/14/2010CA2376159C Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method
09/14/2010CA2373266C Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
09/14/2010CA2322792C Polypeptides homologous to vegf and bmp1
09/14/2010CA2289093C Use of melatonin for preparing medicaments for treating circadian rhythm phase disorders
09/14/2010CA2262014C Adipogenic differentiation of human mesenchymal stem cells
09/14/2010CA2261666C Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
09/14/2010CA2257821C Genes from 20q13 amplicon and their uses
09/14/2010CA2222217C Use of fibroblast growth factors mutants to stimulate bone growth
09/10/2010WO2010102216A2 Enhancing coagulation or reducing fibrinolysis
09/10/2010WO2010101257A1 Agent for preventing recurrence of leukemia
09/10/2010WO2010101072A1 Drug releasing stent
09/10/2010WO2010100686A1 Combination use of cholestanol derivative
09/10/2010WO2010100257A1 Pharmaceutical compositions active in preventing, stabilizing and treating alzheimer's disease
09/10/2010WO2010100063A1 Topical pharmaceutical composition comprising an antiseptic and arginine for wound healing
09/10/2010WO2010100060A2 Method for increasing endogenous plasmalogen levels in mammals
09/10/2010WO2010078916A4 Immunocytokines for tumour therapy with chemotherapeutic agents
09/10/2010CA2754549A1 Enhancing coagulation or reducing fibrinolysis
09/10/2010CA2754075A1 Cholestanol derivative for combined use
09/09/2010US20100227929 Transdermal compositions
09/09/2010US20100227896 Use of vitamin pp compounds
09/09/2010US20100227886 Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases
09/09/2010US20100227885 Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases
09/09/2010US20100227871 Nicotinic receptor agonists for the treatment of inflammatory diseases
09/09/2010US20100227867 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders
09/09/2010US20100227354 Autoimmune Conditions and NADPH Oxidase Defects
09/09/2010US20100226921 Methods for treating obesity using Fibroblast Growth Factor-Like Polypeptides
09/09/2010US20100226880 Treatment with anti-vegf antibodies
09/09/2010DE10336768B4 Medikament zur Verbesserung der Sauerstoffutilation Medication to improve Sauerstoffutilation
09/09/2010DE102009001283A1 Mineralocorticoid receptor antagonist, useful for reducing the myocardial infarction with reperfusion
09/08/2010EP2226632A1 Method for screening of cell-protecting agent
09/08/2010EP2226324A1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines for use in the treatment of diabetes type ii
09/08/2010EP2226318A2 Dye-Azide compounds for dual photherapy
09/08/2010EP2226085A1 Anti-angiogenic compositions and methods of use
09/08/2010EP2226083A1 Drug delivery system
09/08/2010EP2226074A2 Pharmaceutical compositions and their methods of use
09/08/2010EP2226073A1 Topical pharmaceutical composition comprising an antiseptic and arginine for wound healing
09/08/2010EP2226072A1 Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
09/08/2010EP2226066A1 Water-containing composition which can be used as external composition
09/08/2010EP2225254A1 Therapeutic cancer treatments
09/08/2010EP2224931A2 Beta glycolipids for the treatment of calcification related degenerative disorders
09/08/2010EP2224930A1 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
09/08/2010EP2224805A1 Pharmaceutical composition
09/08/2010EP2224804A1 Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
09/08/2010EP1641352B1 Compositions for improved oxidative status in cats
09/08/2010EP1638524B1 Composition and method for the treatment of water related ear disorders
09/08/2010EP1476171B1 Transportation of nucleic acid substances
09/08/2010EP1429797B1 Diagnosis and treatment of malignant neoplasms
09/08/2010EP1412374B1 Novel pgc-1 isoforms and uses therefor
09/08/2010CN1842341B Active fraction having anti-cancer and anti-metastic activity isolated from leaves and stems of ginseng
09/08/2010CN1798746B Reverse-turn mimetics and method relating thereto
09/08/2010CN101827598A Pharmaceutical combination of opioid and prostaglandin compound
09/08/2010CN101824090A Monoclonal antibody hpam4
09/08/2010CN101822841A Application of organic amine derivatives as brain-targeting modification group of small-molecule drug
09/08/2010CN101822837A Medicine composition containing allisartan isoproxil salts
09/08/2010CN101822836A Medicine composition containing allisartan isoproxil
09/08/2010CN101822835A Application of up-regulating folate receptor expression of receptor modulator in enhancing uptake of folate conjugate by tumor cells
09/08/2010CN101822834A Remedy for diabetes
09/08/2010CN101822833A Medicament compound containing theophylines and statins
09/08/2010CN101822832A Composition with anti-tumor effect and application thereof in preparing medicament for treating tumor
09/08/2010CN101822676A Methods of treating patients suffering from movement disorders
09/08/2010CN101822658A Cysteamines for treating complications of hypercholesterolemia and diabetes
09/08/2010CN101822642A Peptide modified invisible nano particle loaded with anti-tumor angiogenesis drug and application thereof
09/08/2010CN101822637A Beta-lactam antibiotics-containing suspension injection
09/08/2010CN101822635A Novel in situ liquid crystal vascular embolization agent
09/08/2010CN101014329B Pharmaceutical composition for preventing or treating rejection reaction of organ or tissue transplant, host resistance reaction of implant in bone marrow transplantation
09/07/2010US7790902 tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents
09/07/2010US7790768 Method for increasing hair growth
09/07/2010US7790749 Antiulcer agents; gastrointestinal disorders; anticancer agents; anemia
09/07/2010US7790738 Methods of treating and preventing AIDS using of COX-2 inhibitors
09/07/2010US7790704 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; thrombocytopenia and megakaryocytopoiesis treatment
09/07/2010US7790674 Treating inflammatory disease; use in combination with other antiinflammatory agents such as anakinra; rheumatoid arthritis for example; Ang-2 inhibitor peptides of amino acid sequence WDPWT
09/07/2010US7790672 Method of using lectins for prevention and treatment of oral and alimentary tract disorders
09/07/2010US7790669 Parkinson's disease, Alzheimer's disease or Huntington's disease or a neurological injury that results from ischemia such as a stroke; tissue repair
09/07/2010US7790458 Nutrient broth for expanding glycoprotein (CD34) expressing cells; reconstituting, repairing and regenerating tissue damage; tissue engineering
09/07/2010US7790408 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
09/07/2010US7790198 Preparation and administration form comprising an acid-labile active compound
09/07/2010US7790193 Inhibiting proliferation with a matrix of alginate polymers and Strontium coated onto a medical, implantable device: a stent, a cardiac pacemaker, a catheter, a implantable prosthetic, a surgical screw, a surgical wire, a tissue bulking implant
1 ... 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 ... 1151